| Literature DB >> 29654657 |
Xin Feng1,2, Ge-Jia Zhong2, Da Ji Deng Ba2, Bin Yang1, Lvyi Chen3,4, Shouying Du1.
Abstract
Tibetan medicine Herpetospermum caudigerum Wall. (HCW) has long been employed to treat hepatitis, inflammatory diseases and jaundice according to the records of "The Four Medical Tantras" in China. This study was investigated to explore the protective effects of HCW on hepatic fibrosis and the possible mechanism in a rat model. Hepatic fibrosis was established by intragastric administration of 3 ml/kg carbon tetrachloride (CCl4 ) twice a week for 6 weeks. CCl4 -treated rats were received HCW (1 and 3 g/kg/d) and silymarin (0.1 g/kg/d) from 3 to 6 weeks. The results showed that HCW could significantly decrease the levels of AST, ALT, HA, LN, PCIII, Col IV, TNF-α, IL-1β and IL-6. Moreover, HCW could effectively inhibit collagen deposition and reduce the pathological damage. Analysis experiments finally exhibited that HCW was able to markedly inhibit hepatic fibrosis by modulating the expressions of NF-κB p65, IκBα, Samd3 and TGF-β1 proteins. Therefore, our results suggest that HCW has hepatoprotective activity against CCl4 -induced hepatic fibrosis in rats by regulating the inflammatory responses.Entities:
Keywords: Herpetospermum caudigerum Wall.; Tibetan medicine; carbon tetrachloride; hepatic fibrosis; inflammation
Mesh:
Substances:
Year: 2018 PMID: 29654657 PMCID: PMC6010801 DOI: 10.1111/jcmm.13568
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1HPLC chromatogram of EAF. (1) Dehydrodiconiferyl alcohol; (2) Herpetrione; (3) Herpetin; (4) Herpetotriol
Figure 2Effect of Herpetospermum caudigerum Wall. (HCW) on serum AST and ALT and TNF‐α, IL‐6 and IL‐1β in serum and liver. Values are expressed as mean ± SD. # P < .05, ## P < .01 as compared with the normal control group; *P < .05, **P < .01 as compared with the CCl4‐treated model group
Effect of Herpetospermum caudigerum Wall. (HCW) on serum levels of hyaluronic acid (HA), laminin (LN), PCIII and Col IV
| Groups | HA (μg/L) | LN (μg/L) | PCIII (μg/L) | Col IV (μg/L) |
|---|---|---|---|---|
| Control | 49.35 ± 5.26 | 73.55 ± 13.06 | 75.57 ± 5.11 | 58.75 ± 23.14 |
| CCl4‐treated model | 75.37 ± 22.65 | 131.74 ± 20.94 | 117.65 ± 29.45 | 75.15 ± 14.70 |
| silymarin (0.1 g/kg) | 39.94 ± 12.61 | 112.87 ± 16.94 | 88.60 ± 6.92 | 56.75 ± 15.14 |
| HCW (1 g/kg) | 61.27 ± 8.46 | 110.38 ± 27.89 | 98.38 ± 10.28 | 54.86 ± 16.03 |
| HCW (3 g/kg) | 54.97 ± 8.63 | 108.78 ± 6.61 | 93.11 ± 10.19 | 46.31 ± 10.88 |
Values are expressed as mean ± SD. # P < .05, ## P < .01, ### P < .001 as compared with the normal control group; *P < .05, **P < .01, ***P < .001 as compared with the CCl4‐treated model group.
Figure 3Effect of Herpetospermum caudigerum Wall. (HCW) against CCl4‐induced hepatic fibrosis in rats. A: HE staining; B and C: Immunohistochemical analysis of TGF‐β1(B) and p‐NF‐κB p65 (C). Magnification: 200 ×
Figure 4Effects of HCW on inflammation‐related pathways in CCl4‐treated rats. Values are expressed as mean ± SD. # P < .05, ## P < .01 as compared with the normal control group; *P < .05, **P < .01 as compared with the CCl4‐treated model group